HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.
September 20, 2023 | 8:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics has received a reiterated 'Buy' rating and a maintained price target of $51 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Arcturus Therapeutics. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100